Other Janus Kinase Inhibitors
| JAK inhibitor | Route | Target | Current clinical trials or reported use |
|---|---|---|---|
| Delgocitinib | Topical | Pan-JAK | Atopic dermatitis, discoid lupus, chronic hand eczema |
| Cerdulatinib | Topical | Pan-JAK, SYK | Vitiligo |
| Gusacitinib | Oral | Pan-JAK, SYK | Atopic dermatitis |
| Peficitinib | Oral | Pan-JAK | Psoriasis |
| Beprocitinib | Oral | JAK1/TK2 | Alopecia areata; atopic dermatitis; hidradenitis suppurativa; plaque psoriasis; psoriatic arthritis, vitiligo |
| Itacitinib | Oral | JAK-1,2 | Psoriasis, melanoma, chronic itch |
| Filgotinib | Oral | JAK1 | Cutaneous lupus |
| Lestaurtinib | Oral | JAK2 | Psoriasis |
| Deucravacitinib | Oral | Regulatory domain of TYK2 | Psoriasis. Note: initial studies showed no laboratory abnormalities, as seen with other JAK inhibitors |
| Ritlecitinib | Oral | JAK3/TEC | Alopecia areata (phase III), vitiligo (phase II) |